All In Biotech

Drug Trial Radar · NCT00301392

Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)

Last checked: Nov 19, 2026Latest source record: Sep 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,240

Actual

Start

Apr 2006

Primary completion

Mar 2012

Study completion Jun 2012

Sponsor

Lead sponsor
Tokyo UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 30 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of pitavastatin for preventing diabetes in a population with impaired glucose tolerance.

Conditions

  • Diabetes Mellitus
  • Glucose Intolerance

Interventions

  • life-style interventionOther

    As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.

  • Life style interventions plus concomitant use of pitavastatin.Drug

    Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative incidence of diabetes based on 1 positive OGTT or fasting glucose levelsTime frame: from April, 2006 to end of March, 2012

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Tokyo, Graduate School of Medicine

    Bunkyo-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.